Inhibition of TCF4/ITF2 in the Treatment of Cancer

The inhibitor of TCF4/ITF2 for use according to any of the foregoing claims wherein the inhibitor of TCF4/ITF2 is a specific inhibitor of TCF4/ITF2, and is selected from a DNA nuclease specifically knocking out or disrupting TCF4/ITF2, an RNase specifically targeting TCF4/ITF2, or an inhibitory oligonucleotide specifically targeting TCF4/ITF2.

An immune checkpoint inhibitor for use in treating or inhibiting cancer, or for use in inhibiting progression, relapse or metastasis of cancer, in combination with an inhibitor of transcription factor 4 (TCF4/ITF2).

A combination of an inhibitor of transcription factor 4 (TCF4/ITF2) and an immune checkpoint inhibitor.

A method for determining or predicting response of a cancer patient to immune checkpoint inhibitor therapy or to therapy comprising an immune checkpoint inhibitor, comprising:

• determining, assessing, measuring, or quantifying the level of TCF4/ITF2 expression in a sample obtained from a cancer lesion, wherein the sample is obtained after the patient having cancer received at least one administration of an immune checkpoint inhibitor therapy or of a therapy comprising an immune checkpoint inhibitor;
• determining or predicting the cancer patient having cancer to respond to the immune checkpoint inhibitor therapy or therapy comprising the immune checkpoint inhibitor when the TCF4/ITF2 expression level in the sample corresponds to TCF4/ITF2 expression levels in the same type of cancer of patients known to respond to the immune checkpoint inhibitor therapy or to the therapy comprising an immune checkpoint inhibitor.

A method for determining or predicting response of a cancer patient to immune checkpoint inhibitor therapy or to therapy comprising an immune checkpoint inhibitor, comprising:

• determining, assessing, measuring, or quantifying the number of mesenchymal-like cancer cells in a sample obtained from a cancer lesion, wherein the sample is obtained after the patient having cancer received at least one administration of an immune checkpoint inhibitor therapy or of a therapy comprising an immune checkpoint inhibitor;
• determining or predicting the cancer patient having cancer to respond to the immune checkpoint inhibitor therapy or therapy comprising the immune checkpoint inhibitor when the number of mesenchymal-like cancer cells in the sample corresponds to the number of mesenchymal-like cancer cells in the same type of cancer of patients known to respond to the immune checkpoint inhibitor therapy or to the therapy comprising an immune checkpoint inhibitor.

A method of determining the presence of mesenchymal-like cancer cells in a tumor, comprising detecting co-localization of a product of a gene of Table 1 or 3, a product of a gene of Table 4 or 5, and a product of a cancer cell gene in the same cancer cell in a sample obtained from a patient having cancer, and designating such cancer cell as mesenchymal-like cancer cell.